Abstract: The present invention related to stable N-((1R,2R)-1-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl) -1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl) octanamide (2R,3R)-2,3-dihydroxysuccinate premix of formula (Ia) and its process for preparation thereof.

Abstract: The present invention relates to sesterterpene compounds, to the precursors thereof that are hydrolysable in a living body, or to the pharmaceutically acceptable salts thereof, and also relates to the prevention and treatment efficacy of the sesterterpene compounds with respect to non-insulin dependent diabetes mellitus, diabetic complications (renal failure and foot ulcers caused by diabetes), alcoholic, non-alcoholic, and viral fatty liver diseases, obesity, hyperlipidemia, atherosclerosis, cardiovascular diseases such as atherosclerotic stroke, and cerebropathies (Parkinsonism, schizophrenia and Alzheimer's disease). In addition, the present invention relates to compositions for functional foods, functional beverages, functional cosmetics, and functional feed.